Financial Survey: Prosensa (RNA) versus The Competition

Prosensa (NASDAQ: RNA) is one of 5 public companies in the “Biotechnology & Medical Research – NEC” industry, but how does it weigh in compared to its peers? We will compare Prosensa to related businesses based on the strength of its profitability, analyst recommendations, institutional ownership, earnings, dividends, valuation and risk.

Earnings and Valuation

This table compares Prosensa and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Prosensa N/A N/A -37.30
Prosensa Competitors $1.34 billion $80.40 million -262.46

Prosensa’s peers have higher revenue and earnings than Prosensa. Prosensa is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

62.1% of shares of all “Biotechnology & Medical Research – NEC” companies are owned by institutional investors. 9.0% of shares of all “Biotechnology & Medical Research – NEC” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Prosensa and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prosensa 0 0 0 0 N/A
Prosensa Competitors 17 128 165 1 2.48

As a group, “Biotechnology & Medical Research – NEC” companies have a potential upside of 41.44%. Given Prosensa’s peers higher possible upside, analysts plainly believe Prosensa has less favorable growth aspects than its peers.


This table compares Prosensa and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Prosensa N/A -72.90% -57.94%
Prosensa Competitors -8,613.35% 2.38% -0.33%


Prosensa peers beat Prosensa on 6 of the 8 factors compared.

About Prosensa

Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company’s primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease. The Company’s clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company’s platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.

Receive News & Ratings for Prosensa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prosensa and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit